Outcome |
Relative effect 95%CI |
LoD |
Trt. better when |
|
I2 |
k (RCT/OBS)
|
Bayesian probability
|
Overall ROB
|
Publication bias |
Degree of certainty |
Endpoint importance |
Published MA |
efficacy endpoints 00 |
deaths (OS) | 0.76 [0.67, 0.87] | | < 1 | | 0% | 4 studies (4/-) | 100.0 % | some concern | not evaluable | moderate | crucial | - |
deaths (OS) (extension) | 0.69 [0.57, 0.84] | | < 1 | | 0% | 1 study (1/-) | 100.0 % | NA | not evaluable | | important | - |
progression or deaths (PFS) | 0.61 [0.50, 0.76] | | < 1 | | 61% | 4 studies (4/-) | 100.0 % | some concern | not evaluable | moderate | important | - |
DCR | 1.15 [0.79, 1.68] | | > 1 | | 0% | 1 study (1/-) | 76.8 % | NA | not evaluable | | non important | - |
DOR | 0.41 [0.20, 0.83] | | < 1 | | 0% | 1 study (1/-) | 99.3 % | NA | not evaluable | | non important | - |
objective responses (ORR) | 2.67 [0.91, 7.79] | | > 1 | | 89% | 4 studies (4/-) | 96.3 % | low | not evaluable | high | non important | - |
safety endpoints 00 |
AE (any grade) | 4.25 [1.40, 12.93] | | < 1 | | 0% | 2 studies (2/-) | 0.5 % | low | not evaluable | high | non important | - |
AE (grade 3-4) | 3.17 [2.27, 4.43] | | < 1 | | 0% | 2 studies (2/-) | 0.0 % | low | not evaluable | high | non important | - |
AE leading to death (grade 5) | 2.39 [0.21, 27.48] | | < 1 | | 0% | 2 studies (2/-) | 24.4 % | low | not evaluable | high | non important | - |
AE leading to treatment discontinuation (any grade) | 2.58 [1.16, 5.75] | | < 1 | | 0% | 1 study (1/-) | 1.0 % | NA | not evaluable | | non important | - |
TRAE (any grade) | 1.35 [0.36, 5.03] | | < 1 | | 95% | 4 studies (4/-) | 32.7 % | some concern | not evaluable | moderate | non important | - |
TRAE (grade 3-4) | 1.75 [0.36, 8.49] | | < 1 | | 96% | 4 studies (4/-) | 24.6 % | some concern | not evaluable | moderate | non important | - |
TRAE leading to death (grade 5) | 1.62 [0.21, 12.60] | | < 1 | | 0% | 3 studies (3/-) | 32.4 % | some concern | not evaluable | moderate | non important | - |
TRAE leading to discontinuation (any grade) | 1.62 [0.86, 3.05] | | < 1 | | 36% | 3 studies (3/-) | 6.8 % | some concern | not evaluable | moderate | non important | - |
TRAE leading to discontinuation (grade 3-4) | 2.06 [0.87, 4.87] | | < 1 | | 0% | 2 studies (2/-) | 5.1 % | some concern | not evaluable | moderate | non important | - |
TRAE (grade 3-4) endpoints 00 |
Alopecia TRAE (grade 3-4) | 0.96 [0.06, 15.38] | | < 1 | | 0% | 2 studies (2/-) | 51.2 % | some concern | not evaluable | moderate | non important | - |
Anaemia TRAE (grade 3-4) | 0.08 [0.01, 0.43] | | < 1 | | 0% | 2 studies (2/-) | 99.8 % | some concern | not evaluable | moderate | non important | - |
Arthralgia TRAE (grade 3-4) | 0.96 [0.13, 6.84] | | < 1 | | 0% | 2 studies (2/-) | 51.7 % | some concern | not evaluable | moderate | non important | - |
Asthenia TRAE (grade 3-4) | 0.96 [0.13, 6.84] | | < 1 | | 0% | 2 studies (2/-) | 51.7 % | some concern | not evaluable | moderate | non important | - |
Colitis TRAE (grade 3-4) | 2.86 [0.59, 13.95] | | < 1 | | 0% | 3 studies (3/-) | 9.8 % | some concern | not evaluable | moderate | non important | - |
Constipation TRAE (grade 3-4) | 0.96 [0.06, 15.38] | | < 1 | | 0% | 2 studies (2/-) | 51.2 % | some concern | not evaluable | moderate | non important | - |
Decreased appetite TRAE (grade 3-4) | 0.96 [0.06, 15.38] | | < 1 | | 0% | 2 studies (2/-) | 51.2 % | some concern | not evaluable | moderate | non important | - |
Diarrhoea TRAE (grade 3-4) | 1.62 [0.16, 16.38] | | < 1 | | 64% | 3 studies (3/-) | 34.2 % | some concern | not evaluable | moderate | non important | - |
Dry skin TRAE (grade 3-4) | 0.96 [0.06, 15.38] | | < 1 | | 0% | 2 studies (2/-) | 51.2 % | some concern | not evaluable | moderate | non important | - |
Fatigue TRAE (grade 3-4) | 0.23 [0.08, 0.70] | | < 1 | | 0% | 2 studies (2/-) | 99.5 % | some concern | not evaluable | moderate | non important | - |
Hepatitis TRAE (grade 3-4) | 3.82 [0.58, 24.96] | | < 1 | | 0% | 3 studies (3/-) | 8.2 % | some concern | not evaluable | moderate | non important | - |
Hyperthyroidism TRAE (grade 3-4) | 0.98 [0.10, 9.42] | | < 1 | | 0% | 3 studies (3/-) | 50.8 % | some concern | not evaluable | moderate | non important | - |
Hypophysitis TRAE (grade 3-4) | 1.43 [0.11, 18.64] | | < 1 | | 0% | 2 studies (2/-) | 39.4 % | some concern | not evaluable | moderate | non important | - |
Hypothyroidism TRAE (grade 3-4) | 0.98 [0.10, 9.42] | | < 1 | | 0% | 3 studies (3/-) | 50.8 % | some concern | not evaluable | moderate | non important | - |
Increase AST TRAE (grade 3-4) | 52.70 [7.19, 385.99] | | < 1 | | 0% | 1 study (1/-) | 0.0 % | NA | not evaluable | | non important | - |
Increased ALT TRAE (grade 3-4) | 32.40 [7.79, 134.72] | | < 1 | | 0% | 1 study (1/-) | 0.0 % | NA | not evaluable | | non important | - |
Leucopenia TRAE (grade 3-4) | 0.07 [0.01, 0.50] | | < 1 | | 0% | 2 studies (2/-) | 99.5 % | some concern | not evaluable | moderate | non important | - |
Maculopapular rash TRAE (grade 3-4) | 1.92 [0.17, 21.29] | | < 1 | | 0% | 2 studies (2/-) | 29.9 % | some concern | not evaluable | moderate | non important | - |
Myalgia TRAE (grade 3-4) | 1.21 [0.17, 8.64] | | < 1 | | 0% | 2 studies (2/-) | 42.5 % | some concern | not evaluable | moderate | non important | - |
Nausea TRAE (grade 3-4) | 0.18 [0.03, 1.07] | | < 1 | | 0% | 2 studies (2/-) | 97.0 % | some concern | not evaluable | moderate | non important | - |
Neutropenia TRAE (grade 3-4) | 0.08 [0.01, 0.60] | | < 1 | | 0% | 2 studies (2/-) | 99.3 % | some concern | not evaluable | moderate | non important | - |
Pancreatitis TRAE (grade 3-4) | 1.42 [0.11, 18.63] | | < 1 | | 0% | 2 studies (2/-) | 39.4 % | some concern | not evaluable | moderate | non important | - |
Paraesthesia TRAE (grade 3-4) | 0.96 [0.06, 15.38] | | < 1 | | 0% | 2 studies (2/-) | 51.2 % | some concern | not evaluable | moderate | non important | - |
Peripheral neuropathy TRAE (grade 3-4) | 0.24 [0.03, 2.13] | | < 1 | | 0% | 2 studies (2/-) | 89.9 % | some concern | not evaluable | moderate | non important | - |
Pneumonitis TRAE (grade 3-4) | 3.58 [0.38, 34.02] | | < 1 | | 0% | 2 studies (2/-) | 13.5 % | some concern | not evaluable | moderate | non important | - |
Pruritus TRAE (grade 3-4) | 2.97 [0.40, 22.18] | | < 1 | | 0% | 3 studies (3/-) | 14.5 % | some concern | not evaluable | moderate | non important | - |
Rash TRAE (grade 3-4) | 2.26 [0.29, 17.34] | | < 1 | | 0% | 3 studies (3/-) | 21.8 % | some concern | not evaluable | moderate | non important | - |
Thrombocytopenia TRAE (grade 3-4) | 0.18 [0.03, 1.07] | | < 1 | | 0% | 2 studies (2/-) | 97.0 % | some concern | not evaluable | moderate | non important | - |
Thyroiditis TRAE (grade 3-4) | 1.02 [0.02, 51.42] | | < 1 | | 0% | 1 study (1/-) | 49.7 % | NA | not evaluable | | non important | - |
Uveitis TRAE (grade 3-4) | 1.42 [0.11, 18.63] | | < 1 | | 0% | 2 studies (2/-) | 39.4 % | some concern | not evaluable | moderate | non important | - |
Vitiligo TRAE (grade 3-4) | 0.96 [0.06, 15.38] | | < 1 | | 0% | 2 studies (2/-) | 51.2 % | some concern | not evaluable | moderate | non important | - |
Vomiting TRAE (grade 3-4) | 0.24 [0.05, 1.12] | | < 1 | | 0% | 2 studies (2/-) | 96.5 % | some concern | not evaluable | moderate | non important | - |
AE (grade 3-4) endpoints 00 |
Abdominal pain AE (grade 3-4) | 0.43 [0.11, 1.68] | | < 1 | | 0% | 1 study (1/-) | 88.8 % | NA | not evaluable | | non important | - |
Asthenia AE (grade 3-4) | 0.17 [0.02, 1.39] | | < 1 | | 0% | 1 study (1/-) | 95.0 % | NA | not evaluable | | non important | - |
Chills AE (grade 3-4) | 1.02 [0.02, 51.42] | | < 1 | | 0% | 1 study (1/-) | 49.7 % | NA | not evaluable | | non important | - |
Constipation AE (grade 3-4) | 1.02 [0.02, 51.42] | | < 1 | | 0% | 1 study (1/-) | 49.7 % | NA | not evaluable | | non important | - |
Cough AE (grade 3-4) | 2.04 [0.07, 60.99] | | < 1 | | 0% | 1 study (1/-) | 34.3 % | NA | not evaluable | | non important | - |
Decreased appetite AE (grade 3-4) | 0.76 [0.17, 3.43] | | < 1 | | 0% | 1 study (1/-) | 63.9 % | NA | not evaluable | | non important | - |
Diarrhoea AE (grade 3-4) | 21.14 [1.23, 363.94] | | < 1 | | 0% | 1 study (1/-) | 1.9 % | NA | not evaluable | | non important | - |
Dyspnoea AE (grade 3-4) | 16.77 [0.96, 293.61] | | < 1 | | 0% | 1 study (1/-) | 2.8 % | NA | not evaluable | | non important | - |
Fatigue AE (grade 3-4) | 2.44 [1.21, 4.94] | | < 1 | | 0% | 1 study (1/-) | 0.6 % | NA | not evaluable | | non important | - |
Headache AE (grade 3-4) | 4.12 [0.46, 37.08] | | < 1 | | 0% | 1 study (1/-) | 10.5 % | NA | not evaluable | | non important | - |
Increase AST AE (grade 3-4) | 18.42 [5.64, 60.14] | | < 1 | | 0% | 1 study (1/-) | 0.0 % | NA | not evaluable | | non important | - |
Increased ALT AE (grade 3-4) | 34.83 [8.39, 144.67] | | < 1 | | 0% | 1 study (1/-) | 0.0 % | NA | not evaluable | | non important | - |
Nausea AE (grade 3-4) | 1.36 [0.30, 6.14] | | < 1 | | 0% | 1 study (1/-) | 34.5 % | NA | not evaluable | | non important | - |
Pruritus AE (grade 3-4) | 10.35 [0.56, 190.49] | | < 1 | | 0% | 1 study (1/-) | 6.0 % | NA | not evaluable | | non important | - |
Pyrexia AE (grade 3-4) | 1.02 [0.02, 51.42] | | < 1 | | 0% | 1 study (1/-) | 49.7 % | NA | not evaluable | | non important | - |
Rash AE (grade 3-4) | 6.16 [0.31, 123.62] | | < 1 | | 0% | 1 study (1/-) | 12.0 % | NA | not evaluable | | non important | - |
Vomiting AE (grade 3-4) | 2.07 [0.61, 6.95] | | < 1 | | 0% | 1 study (1/-) | 12.1 % | NA | not evaluable | | non important | - |
Weight decreased AE (grade 3-4) | 1.02 [0.06, 16.34] | | < 1 | | 0% | 1 study (1/-) | 49.6 % | NA | not evaluable | | non important | - |